Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: or a pharmaceutically acceptable salt, wherein the variables are as defined herein. Moreover, The compounds of this invention have formula I-A: or a pharmaceutically acceptable salt, wherein the variables are as defined herein.

Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: or a pharmaceutically acceptable salt, wherein the variables are as devined herein. Moreover, The compounds of this invention have formula I-A: or a pharmaceutically acceptable salt, wherein the variables are as defined herein.

Abstract: In one aspect, an example computer-implemented method includes (a) receiving, by a computing system, data associated with a user; (b) generating, by the computing system, one or more entries in a persistently stored structure based on the data; (c) determining, by the computing system, a value from the one or more entries; (d) providing, by the computing system and to a client computing device, a report comprising, at least in part, information associated with the one or more entries; and (e) issuing, by the computing system and to the user, a digital token that is based on, at least in part, the value from the one or more entries.

Abstract: The present disclosure relates to medical devices that that include the following: a flexible elongate tube having a proximal end and a distal end configured to be directed toward an opening of a body lumen; a first lumen extending from the distal end of the tube proximally along the tube and having a fluid connection for a fluid source at its proximal end; a second lumen extending from the distal end of the tube proximally along the tube, the second lumen configured to accept a guidewire extending along the second lumen; and a wire filament extending along the elongate tube, a distal end of the filament connected to the distal end of the elongate tube, a proximal portion of the wire extending at least partially along the elongate tube, and a distal portion of the wire extending external to the elongate tube.

Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: or a pharmaceutically acceptable salt, wherein the variables are as devined herein. Moreover, The compounds of this invention have formula I-A: or a pharmaceutically acceptable salt, wherein the variables are as defined herein.

Abstract: A brake system includes a series of rotors for operatively coupling to a shaft and stators for operatively coupling to a frame. A service brake system includes a singular annular service piston extending continuously around the series of rotors and stators and a parking brake system includes a singular annular parking piston positioned to extend continuously around the series of rotors and stators. The service piston nests with the parking piston, under a spring bias, such that the parking piston and service piston continuously engage together around the series of rotors and stators to thereby create the parking brake forces. Springs act on the parking piston to drive the parking piston and nested service piston to engage for parking brake forces. Pressurization of the parking piston deactuates the nested pistons. Then separate pressurization of fluid acts on the service piston to overcome the spring bias and separate the service piston from the parking piston to create service brake forces.

Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: or a pharmaceutically acceptable salt, wherein the variables are as devined herein. Moreover, The compounds of this invention have formula I-A: or a pharmaceutically acceptable salt, wherein the variables are as defined herein.

Abstract: A brake system for a piece of equipment includes a series of rotors and stators, and a first brake actuator including at least one first piston positioned within a first chamber such that pressurization of the first chamber causes the at least one first piston to operatively engage at least one of rotors or stators such that the rotors and stators are compressed together and thereby create braking torque, and may also include a second brake actuator including at least one spring operatively coupled to at least one second piston positioned within a second chamber such that depressurization of the second chamber causes the at least one second piston to operatively engage at least one of the rotors or stators such that the pluralities of rotors and stators are compressed together and thereby create braking torque.

Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: or a pharmaceutically acceptable salt, wherein the variables are as devined herein. Moreover, The compounds of this invention have formula I-A: or a pharmaceutically acceptable salt, wherein the variables are as defined herein.

Abstract: A brake system for a piece of equipment includes a series of rotors and stators, and a first brake actuator including at least one first piston positioned within a first chamber such that pressurization of the first chamber causes the at least one first piston to operatively engage at least one of rotors or stators such that the rotors and stators are compressed together and thereby create braking torque, and may also include a second brake actuator including at least one spring operatively coupled to at least one second piston positioned within a second chamber such that depressurization of the second chamber causes the at least one second piston to operatively engage at least one of the rotors or stators such that the pluralities of rotors and stators are compressed together and thereby create braking torque.

Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and solid forms of the compounds of this invention. The compounds of this invention have formula I-1 or I-A: wherein the variables are as defined herein.

Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: or a pharmaceutically acceptable salt, wherein the variables are as devined herein. Moreover, The compounds of this invention have formula I-A: or a pharmaceutically acceptable salt, wherein the variables are as defined herein.

Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: or a pharmaceutically acceptable salt, wherein the variables are as devined herein. Moreover, The compounds of this invention have formula I-A: or a pharmaceutically acceptable salt, wherein the variables are as defined herein.

Abstract: The present disclosure relates generally to the field of medical devices and establishing access to body lumens. In particular, the present disclosure relates to medical devices, systems and methods for facilitating access to an opening of a body lumen through an endoscope by at least partially dilating the opening with fluid from a fluid source prior to contacting the body lumen.

Abstract: A hybrid wheel for vehicles that includes a unitary lug structure, with a mount face and a dish section of the lug structure extending therefrom. The lug structure is usually a cast aluminum alloy. A wheel structure including a high strength polymer encapsulates a portion of the lug structure dish section. Rim ring(s) are included in the wheel structure and are preferably made of a fiber reinforced high strength polymer.

Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: or a pharmaceutically acceptable salt, wherein the variables are as devined herein. Moreover, The compounds of this invention have formula I-A: or a pharmaceutically acceptable salt, wherein the variables are as defined herein.

Abstract: A brake system for a piece of equipment includes a series of rotors and stators, and a first brake actuator including at least one first piston positioned within a first chamber such that pressurization of the first chamber causes the at least one first piston to operatively engage at least one of rotors or stators such that the rotors and stators are compressed together and thereby create braking torque, and may also include a second brake actuator including at least one spring operatively coupled to at least one second piston positioned within a second chamber such that depressurization of the second chamber causes the at least one second piston to operatively engage at least one of the rotors or stators such that the pluralities of rotors and stators are compressed together and thereby create braking torque.

Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and solid forms of the compounds of this invention. The compounds of this invention have formula I-1 or I-A: wherein the variables are as defined herein.

Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and solid forms of the compounds of this invention. The compounds of this invention have formula I-1 or I-A: wherein the variables are as defined herein.

Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: or a pharmaceutically acceptable salt, wherein the variables are as devined herein. Moreover, The compounds of this invention have formula I-A: or a pharmaceutically acceptable salt, wherein the variables are as defined herein.